These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35953818)

  • 1. Ryanodine receptor 1-mediated Ca
    Zhang L; Au-Yeung CL; Huang C; Yeung TL; Ferri-Borgogno S; Lawson BC; Kwan SY; Yin Z; Wong ST; Thomas V; Lu KH; Yip KP; Sham JSK; Mok SC
    J Exp Clin Cancer Res; 2022 Aug; 41(1):242. PubMed ID: 35953818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.
    Black J; Menderes G; Bellone S; Schwab CL; Bonazzoli E; Ferrari F; Predolini F; De Haydu C; Cocco E; Buza N; Hui P; Wong S; Lopez S; Ratner E; Silasi DA; Azodi M; Litkouhi B; Schwartz PE; Goedings P; Beusker PH; van der Lee MM; Timmers CM; Dokter WH; Santin AD
    Mol Cancer Ther; 2016 Aug; 15(8):1900-9. PubMed ID: 27256376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced threshold for store overload-induced Ca
    Chen W; Koop A; Liu Y; Guo W; Wei J; Wang R; MacLennan DH; Dirksen RT; Chen SRW
    Biochem J; 2017 Aug; 474(16):2749-2761. PubMed ID: 28687594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma.
    O'Connor CM; Taylor SE; Miller KM; Hurst L; Haanen TJ; Suhan TK; Zawacki KP; Noto FK; Trako J; Mohan A; Sangodkar J; Zamarin D; DiFeo A; Narla G
    Cancer Res; 2022 Feb; 82(4):721-733. PubMed ID: 34921012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.
    Lopez S; Cocco E; Black J; Bellone S; Bonazzoli E; Predolini F; Ferrari F; Schwab CL; English DP; Ratner E; Silasi DA; Azodi M; Schwartz PE; Terranova C; Angioli R; Santin AD
    Mol Cancer Ther; 2015 Nov; 14(11):2519-26. PubMed ID: 26333383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphorylation of STAT1 serine 727 enhances platinum resistance in uterine serous carcinoma.
    Zeng X; Baba T; Hamanishi J; Matsumura N; Kharma B; Mise Y; Abiko K; Yamaguchi K; Horikawa N; Hunstman DG; Mulati K; Kitamura S; Taki M; Murakami R; Hosoe Y; Mandai M
    Int J Cancer; 2019 Sep; 145(6):1635-1647. PubMed ID: 31228268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma.
    Han C; Perrone E; Zeybek B; Bellone S; Tymon-Rosario J; Altwerger G; Menderes G; Feinberg J; Haines K; Muller Karger ME; Bianchi A; Zammataro L; Manzano A; Bonazzoli E; Manara P; Buza N; Hui P; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Lopez S; Santin AD
    Gynecol Oncol; 2020 Feb; 156(2):430-438. PubMed ID: 31839338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity.
    Zhao F; Li P; Chen SR; Louis CF; Fruen BR
    J Biol Chem; 2001 Apr; 276(17):13810-6. PubMed ID: 11278295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.
    Schwab CL; Bellone S; English DP; Roque DM; Lopez S; Cocco E; Nicoletti R; Bortolomai I; Bonazzoli E; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
    Br J Cancer; 2014 Oct; 111(9):1750-6. PubMed ID: 25268372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype.
    Hu W; Zhang L; Ferri-Borgogno S; Kwan SY; Lewis KE; Cun HT; Yeung TL; Soliman PT; Tarapore RS; Allen JE; Guan X; Lu KH; Mok SC; Au-Yeung CL
    Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32867127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An RYR1 mutation associated with malignant hyperthermia is also associated with bleeding abnormalities.
    Lopez RJ; Byrne S; Vukcevic M; Sekulic-Jablanovic M; Xu L; Brink M; Alamelu J; Voermans N; Snoeck M; Clement E; Muntoni F; Zhou H; Radunovic A; Mohammed S; Wraige E; Zorzato F; Treves S; Jungbluth H
    Sci Signal; 2016 Jul; 9(435):ra68. PubMed ID: 27382027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu.
    Yadav G; Roque DM; Bellone S; Manavella DD; Hartwich TMP; Zipponi M; Harold J; Tymon-Rosario J; Mutlu L; Altwerger G; Menderes G; Ratner E; Buza N; Hui P; Huang GS; Andikyan V; Clark M; Azodi M; Schwartz PE; Alexandrov LB; Santin AD
    Gynecol Oncol; 2022 Aug; 166(2):351-357. PubMed ID: 35641325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts.
    Groeneweg JW; Hernandez SF; Byron VF; DiGloria CM; Lopez H; Scialabba V; Kim M; Zhang L; Borger DR; Tambouret R; Foster R; Rueda BR; Growdon WB
    Clin Cancer Res; 2014 Dec; 20(24):6517-6528. PubMed ID: 25294905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profiles in stage I uterine serous carcinoma in comparison to grade 3 and grade 1 stage I endometrioid adenocarcinoma.
    Mhawech-Fauceglia P; Wang D; Kesterson J; Syriac S; Clark K; Frederick PJ; Lele S; Liu S
    PLoS One; 2011 Mar; 6(3):e18066. PubMed ID: 21448288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular alterations in uterine serous carcinoma.
    Hayes MP; Ellenson LH
    Gynecol Oncol; 2010 Feb; 116(2):286-9. PubMed ID: 20109727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.
    English DP; Roque DM; Carrara L; Lopez S; Bellone S; Cocco E; Bortolomai I; Schwartz PE; Rutherford T; Santin AD
    Gynecol Oncol; 2013 Dec; 131(3):753-8. PubMed ID: 24012800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma.
    Matoba Y; Zarrella DT; Pooladanda V; Azimi Mohammadabadi M; Kim E; Kumar S; Xu M; Qin X; Ray LJ; Devins KM; Kumar R; Kononenko A; Eisenhauer E; Veillard IE; Yamagami W; Hill SJ; Sarosiek KA; Yeku OO; Spriggs DR; Rueda BR
    Br J Cancer; 2024 May; 130(9):1463-1476. PubMed ID: 38438589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidative stress-induced FAK activation contributes to uterine serous carcinoma aggressiveness.
    Lopez-Mejia IC; Pijuan J; Navaridas R; Santacana M; Gatius S; Velasco A; Castellà G; Panosa A; Cabiscol E; Pinyol M; Coll L; Bonifaci N; Peña LP; Vidal A; Villanueva A; Gari E; Llobet-Navàs D; Fajas L; Matias-Guiu X; Yeramian A
    Mol Oncol; 2023 Jan; 17(1):98-118. PubMed ID: 36409196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignant hyperthermia-associated mutations in the S2-S3 cytoplasmic loop of type 1 ryanodine receptor calcium channel impair calcium-dependent inactivation.
    Gomez AC; Holford TW; Yamaguchi N
    Am J Physiol Cell Physiol; 2016 Nov; 311(5):C749-C757. PubMed ID: 27558158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of ryanodine receptor type 1 single channel activity using "on-nucleus" patch clamp.
    Wagner LE; Groom LA; Dirksen RT; Yule DI
    Cell Calcium; 2014 Aug; 56(2):96-107. PubMed ID: 24972488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.